3
Announcements
Trials
Browse
Landscape
Phase
Phase EARLY_PHASE1
1
Phase 4
1
Phase 2
1
Phase 1/2
1
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Urinary Bladder Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumor
1
Lymphoma, B-Cell
1
Lymphoma
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hematuria
1
Interventions
Rituximab
5
fludarabine
4
Cyclophosphamide
4
pembrolizumab
2
Bendamustine Hydrochloride
2
68Ga-pentixafor
2
venetoclax
1
pegylated granulocyte colony-stimulating factor, human
1
pegfilgrastim
1
motexafin gadolinium
1
ibrutinib
1
fludarabine phosphate
1
daratumumab
1
brexucabtagene autoleucel
1
acalabrutinib
1
Vincristine
1
Valproic Acid
1
Transplantation
1
Tablets
1
Surveys and Questionnaires
1
Sugars
1
Stem Cell Transplantation
1
Simvastatin
1
Roflumilast
1
Ribavirin
1
Radiotherapy
1
Procarbazine
1
Positron-Emission Tomography
1
Pemetrexed
1
Nivolumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase EARLY_PHASE1
×
Lymphoma
×
Valproic Acid
×
Clear all
NCT02144623
2017-03-03
PREVAIL
Lund University Hospital
Phase EARLY_PHASE1
Completed
4 enrolled